UBI

The Unit for Biomarker Innovation (UBI) at DTU Health Tech’s Centre for Diagnostics (CfD) is an open-access research infrastructure supporting the discovery and development of protein biomarkers and in vitro diagnostic (IVD) tools.

UBI works in close collaboration with clinicians and researchers to:

1. Identify and validate novel biomarkers for diagnostic, prognostic, monitoring, predictive, susceptibility/risk, safety, and pharmacodynamic/response applications.
2. Establish interdisciplinary consortia and co-develop funding proposals aimed at advancing IVD technologies for both central laboratories and point-of-care settings-supporting early diagnosis, therapeutic monitoring, and patient stratification.

Our infrastructure includes advanced proteomics platforms (Olink, Meso Scale, Luminex), supported by laboratory and bioinformatics expertise for both targeted and exploratory studies. Biomarkers-whether discovered at UBI or externally-can be validated for analytical performance in our ISO 17025-accredited laboratory.

UBI also co-develops biological assays in partnership with clinical collaborators, integrating them into DTU prototypes, spinouts, startups, or adapting them to existing diagnostic technologies based on clinical needs.

We welcome collaboration across biomedical sciences and clinical specialties. UBI serves as a shared resource and point of contact for clinicians, academic groups, and industry partners—facilitating translational research and innovation in diagnostics.